ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Price to Sales Ratio (P/S) on January 14, 2025: 19.50

ABL Bio Inc. Price to Sales Ratio (P/S) is 19.50 on January 14, 2025, a 19.45% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

ABL Bio Inc. 52-week high Price to Sales Ratio (P/S) is 28.95 on October 14, 2024, which is 48.50% above the current Price to Sales Ratio (P/S).
ABL Bio Inc. 52-week low Price to Sales Ratio (P/S) is 14.16 on February 08, 2024, which is -27.36% below the current Price to Sales Ratio (P/S).
ABL Bio Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 19.17.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years